US EditionPublished • loading... • Updated
What Clinical and HEOR Evidence Does CMS Expect for IRA Drug Price Negotiations?
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
What Clinical and HEOR Evidence Does CMS Expect for IRA Drug Price Negotiations?
The Inflation Reduction Act (IRA) has fundamentally changed U.S. drug pricing, granting the Centers for Medicare & Medicaid Services (CMS) authority to negotiate prices for high-expenditure Part B and Part D drugs. This negotiation is rooted in evidence, requiring manufacturers to submit detailed, Medicare-centered clinical and economic information to ensure prices reflect real-world clinical value. For Health Economics and Outcomes Research (HE…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
